期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
ALK抑制剂在治疗NSCLC脑转移中的疗效及安全性研究进展 被引量:1
1
作者 陈雨晨 韩寒 +2 位作者 魏晋攀 杜倩宇 王西勇 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第5期400-406,共7页
肺癌是全球死亡率最高的恶性肿瘤之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占所有肺癌病理类型的80%-85%。NSCLC中有30%-55%的患者发生脑转移。据估计,5%-6%的脑转移患者存在间变性淋巴瘤激酶(anaplastic lymphoma kina... 肺癌是全球死亡率最高的恶性肿瘤之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占所有肺癌病理类型的80%-85%。NSCLC中有30%-55%的患者发生脑转移。据估计,5%-6%的脑转移患者存在间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合。ALK融合阳性NSCLC患者在接受ALK抑制剂后获得了非常显著的疗效。经过十余年的迅速发展,ALK抑制剂已经形成三代同堂的局面:即第一代——克唑替尼(Crizotinib);第二代——阿来替尼(Alectinib)、布格替尼(Brigatinib)、塞瑞替尼(Ceritinib)、恩沙替尼(Ensartinib);第三代——洛拉替尼(Lorlatinib)。这些药物在ALK融合阳性NSCLC脑转移患者中显示出不同的疗效。由于此类药物众多,ALK抑制剂的选择给临床医生带来了困扰。因此,本文旨在对ALK抑制剂在NSCLC脑转移中的治疗效果和安全性进行综述,以期为临床医生提供治疗选择的依据。 展开更多
关键词 肺肿瘤 ALK抑制剂 脑转移 疗效 安全性
下载PDF
Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research 被引量:1
2
作者 Man Li Xueli Zhou +5 位作者 Wei Wang Baoan Ji Yu Shao qianyu du Jinghao Yao Yan Yang 《Journal of Clinical and Translational Hepatology》 SCIE 2022年第4期700-710,共11页
Cholangiocarcinoma(CCA)is a highly aggressive biliary tree malignancy with intrahepatic and extra-hepatic sub-types that differ in molecular pathogeneses,epidemiology,clinical manifestations,treatment,and prognosis.Th... Cholangiocarcinoma(CCA)is a highly aggressive biliary tree malignancy with intrahepatic and extra-hepatic sub-types that differ in molecular pathogeneses,epidemiology,clinical manifestations,treatment,and prognosis.The over-all prognosis and patient survival remains poor because of lack of early diagnosis and effective treatments.Preclini-cal in vivo studies have become increasingly paramount as they are helpful not only for the study of the fundamental molecular mechanisms of CCA but also for developing novel and effective therapeutic approaches of this fatal cancer.Recent advancements in cell and molecular biology have made it possible to mimic the pathogenicity of human CCA in chemical-mechanical,infection-induced inflammatory,implantation,and genetically engineered animal models.This review is intended to help investigators understand the particular strengths and weaknesses of the currently used in vivo animal models of human CCA and their related mod-eling techniques to aid in the selection of the one that is the best for their research needs. 展开更多
关键词 CHOLANGIOCARCINOMA HETEROGENEITY Animal model Genetically engineered model Cancer cell of origin
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部